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Abstract
The Grb7 (growth factor receptor-bound 7) protein, a member of the Grb7 protein family, is found to be highly expressed in
such metastatic tumors as breast cancer, esophageal cancer, liver cancer, etc. The src-homology 2 (SH2) domain in the C-
terminus is reported to be mainly involved in Grb7 signaling pathways. Using the random peptide library, we identified a
series of Grb7 SH2 domain-binding nonphosphorylated peptides in the yeast two-hybrid system. These peptides have a
conserved GIPT/K/N sequence at the N-terminus and G/WD/IP at the C-terminus, and the region between the N-and C-
terminus contains fifteen amino acids enriched with serines, threonines and prolines. The association between the
nonphosphorylated peptides and the Grb7 SH2 domain occurred in vitro and ex vivo. When competing for binding to the
Grb7 SH2 domain in a complex, one synthesized nonphosphorylated ligand, containing the twenty-two amino acid-motif
sequence, showed at least comparable affinity to the phosphorylated ligand of ErbB3 in vitro, and its overexpression
inhibited the proliferation of SK-BR-3 cells. Such nonphosphorylated peptides may be useful for rational design of drugs
targeted against cancers that express high levels of Grb7 protein.
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Introduction
Grb7 protein is associated with amplification and invasion of
many solid cancers, including those of the breast [1], esophagus
[2], pancreas [3] and lymphocytic leukemia [4]. Via the SH2
domain, Grb7 protein participates in many signaling pathways,
such as those associated with insulin [5], ErbB2, ErbB3 and ErbB4
[6], FAK [7], c-Kit/SCFR [8] and FGFR [9].
The SH2 domain plays vital roles in signaling pathways by
acting as adaptors, kinases or scaffolds [10]. The SH2 domain
contains a central anti-parallel b sheet surrounded by two a helices
[11]. It has a positively charged binding cavity [12] that promotes
its association with phosphotyrosine motifs [13]. Although
different SH2 domains prefer distinct phosphorylated motifs
[14], certain SH2 domains are more flexible in their motif
preference [15].
SH2 domains also associate with phosphotyrosine-independent
motifs. For instance, the T/S-x-x-x-x-V/I (x represents any amino
acid) motif is recognized by the SAP/SH2D1A SH2 domain [16],
phosphorylated serines and threonines residues are identified by
the SH2 domain of ABL [17], nonphosphorylated peptides are
distinguished by the SH2 domains of Grb2 and Grb7 [18,19], the
nonphosphorylated SIY(442)DNV motif is able to associate with
the cten (C-terminal tensin like) SH2 domain, and the serine and
tyrosine residues in this motif are necessary for the interaction,
further more, a phosphorylation modification on the tyrosine
residue slightly attenuates its affinity to the cten SH2 domain [20].
The Grb7 protein family, identified through cDNA expression
libraries encoding phosphotyrosine receptor targets [21,22], is an
SH2 domain protein clan that recruits downstream molecules and
participates in important cellular signaling pathways [23]. Three
members of this family are Grb7, Grb10 and Grb14. Grb7
participates in cell migration and angiogenesis, Grb10 is involved
in cell metabolic control and development amplification and
Grb14 has roles in cell metabolic regulation and proliferation [23].
Differences exist between the SH2 domain of Grb7 family proteins
and the SH2 domain of other conventional SH2 proteins. The
SH2 domain of Grb7 family members displays a more permissive
structure by having three more residues in the DE loop and five
less residues in the CD loop [24]. SH2 domains of Grb10c and
Grb7 form dimers, whereas other SH2 domains are normally
monosomatic [25]. There are also dissimilarities in the SH2
domains of the three Grb7 family members. Grb10 and Grb14
have the most similar SH2 domain sequences [21], the SH2
domain of Grb10 shares approximately 90% similarity with that of
Grb14. The SH2 domain of Grb7, but not that of Grb10 and
Grb14, associates with b-turn peptides, which is similar to the SH2
domain of Grb2 [26].
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Krag and colleagues have identified a nonphosphorylated peptide,
designated the G7-18NATE, that binds to the SH2 domain of
Grb7. The dissociation constant (Kd) of the G7-18NATE peptide
for binding to the Grb7 SH2 domain is approximately 13.2 mM,
and that of the ErbB3 pY(1180) ligand is approximately 1.15 mM
[27]. The G7-18NATE peptide effectively inhibits the association
between Grb7 and ErbB3 [28], pancreatic cancer migration [3]
and breast cancer cell proliferation [29]. This peptide also serves
as a model for chemical drug design targeting the Grb7 protein
[30].
Results
Novel nonphosphorylated twenty-two amino residue
peptides harboring conserved sequences at both ends
selectively bind to the Grb7 SH2 domain
The Grb7 SH2 domain was used to screen the random peptide
library in the yeast two-hybrid system, and nine positive clones
were identified (Table S1). The twenty-two amino acid sequence
containing GIPT/K/N at the N-terminus and G/W/D/I/P at
the C-terminus was the most notable feature of the positive clones
(Table 1). Although the Grb2 SH2 domain was reported to
recognize nonphosphorylated peptide [18], we did not find any
positive clone binding to the Grb2 SH2 domain in our system,
neither to the ABL_1 SH2 domain.
To see whether the conserved residues were required for
association with the Grb7 SH2 domain, the peptide 10 was used as
the mutation template to design three mutated peptides: the N-
GIPT deletion mutation (10AM), the C-GIP deletion mutation
(10BM) and the both N-GIPT and C-GIP deletion mutation
(10CM). None of the three mutations were recognized by the
Grb7 SH2 domain in the yeast two-hybrid system. This indicates
that the peptide requires the conserved residues at each end to
recognize the Grb7 SH2 domain.
The SH2 domain of Grb14, which is another member of the
Grb7 protein family, was also used to screen the random peptide
library with yeast two-hybrid analysis. However, no positive clone
was identified. The nine clones (Table 1) that bound to the Grb7
SH2 domain also did not interact with the Grb14 SH2 domain.
One nonphosphorylated peptide and the Grb7 SH2
domain are co-immunoprecipitated from transfected
HEK293Tcells
The 10, 41 and 10CM sequences were fused to the mRLUC-
36Flag and co-transfected with the EGFP-Grb7 SH2 into
HEK293T cells using calcium phosphate method respectively.
Fusion protein expression was first verified. The expression of
peptide 10 was low (Figure 1A). In co-immunoprecipitation assays,
peptide 41, but not the peptide 10CM or the control, pulled down
the Grb7 SH2 domain (Figure 1B).
The binding of the Grb7 SH2 domain to the
nonphosphorylated peptides is detected by
Bioluminescence Resonance Energy Transfer (BRET)
The EYFP-tagged Grb7 SH2 domain was co-transfected with
the mRLUC-tagged nonphosphorylated peptides into HEK293T
cells using calcium phosphate (Figure 2A). The EYFP-mRLUC
plasmid was transfected as positive control. The luminescence
ratios of 530/480 nm for the EYFP-mRLUC positive control, the
interacting EYFP-tagged Grb7 SH2 domain and mRLUC-tagged
peptide 10 and 41 groups, were significantly stronger than the
luminescence produced by the non-interacting EYFP-tagged Grb7
SH2 domain and the mRLUC-tagged peptide 10CM or control
vector groups (Figure 2B). The strongest luminescence was
produced by the EYFP-tagged Grb7 SH2 domain and mRLUC-
tagged ErbB3 group.
The nonphosphorylated twenty-two amino acid-motif
ligand has at least comparable affinity to the
phosphorylated ligand for the Grb7 SH2 domain in vitro
To see whether the nonphosphorylated peptide could effectively
compete with phosphorylated ligand for binding to the Grb7 SH2
domain, the phosphorylated ligand pY (1180) (DEEYE-
pY(1180)MNRRR), which was previously shown to interact with
the Grb7 SH2 domain [6], and the nonphosphorylated 41-A
ligand (VAVGIPTQPTTSSEPSPPSNPPWDPGRV), which con-
tains the first twenty-two amino acid-motif close to the N-terminus
of peptide 41, were examine for their abilities to interfere with the
GFP-Grb7 SH2 domain and 41-mRLUC-36Flag complex using
immunoprecipitation with anti-GFP antibody. As shown in
Figure 3A, the nonphosphorylated peptide 41 could bind to the
Grb7 SH2 domain in the absence of peptide pY (1180) and
peptide 41-A. Low concentrations of peptide pY (1180) and
peptide 41-A (0.0072 mM and 0.036 mM) did not significantly
interfere with binding of the Grb7 SH2 domain to peptide 41.
However, concentration of peptide pY (1180) and peptide 41-A
reached 0.18 mM, the interaction between the Grb7 SH2 domain
and peptide 41 was nearly abolished. The disruptive effect of
peptide 41-A was even stronger than that of the pY (1180) ligand,
and phosphorylated peptide pY (1180) (IC50=31.83 mM) and
nonphosphorylated peptide 41-A (IC50=18.78 mM) had at least
comparable binding affinities to the Grb7 SH2 domain.
Because the peptide pY (1180) abolished the association
between the Grb7 SH2 domain and nonphosphorylated peptide
41 (Figure 3A), we speculated that the binding interface of the
Grb7 SH2 domain for the nonphosphorylated twenty-two amino
acid-motif might be the same for the pY(1180) ligand. Structural
modeling based on the Molecular Operating Environment (MOE)
was performed to illustrate the possible binding site (Figure 3B,
right), and the Grb7 SH2/pY (1139) ligand of ErbB2 was used as
control (Figure 3B, left) [31]. In this model, the binding interface
on the SH2 domain with a known structure was set as rigid and
the ligand was set as flexible.
Table 1. Nonphosphorylated peptides interacting with the
Grb7 SH2 domain (abridged sequences of conserved amino
acid sequences).
No. of peptide Sequences
3 and 52
a GIPT HSSPQYSPPSTYSPP GDP
10 GIPN YTPTTPTLLLTRPLP GIP
16 GIPT ATTSPYENANPPHQT WDP
41-A
b
41-B
GIPT QPTTSSEPSPPSNPP WDP
GIPT HHQNDTYNSPHAHPN RDP
60 RNSY FTFLPARSLYLIKTH WDP
67 GIPK AQNTTATPEQHASPT GIP
98 GIPN QDPPAATQSPSQETT WDP
106 GIPT STPNTHSTTSHHKNP WDP
Notes:
a)No. 3 and No. 52 were the same clones.
b)There were two twenty-two residue motifs in the peptide No. 41, with sixteen
residues between them, designated 41-A and 41-B, respectively. The full
nonphosphorylated peptide sequences were accessible in Table S1.
doi:10.1371/journal.pone.0029902.t001
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SK-BR-3 breast cancer cells
The effect of nonphosphorylated peptide 41 on the proliferation
of SK-BR-3 breast cancer cells, which express high levels of the
Grb7 protein [32], was evaluated using the MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophe-
nyl)-2H-tetrazolium, inner salt) cell proliferation assay. Endoge-
nous expression of the Grb7 protein and expression of the fusion
protein of 41-mRLUC-36Flag in SK-BR-3 breast cancer cells
were first verified (Figure 4A). Beginning from 24 h, the
absorbance of the 41-mRLUC-36Flag group indicated that the
proliferation of 41-mRLUC-36Flag-transfected SK-BR-3 breast
cancer cells was significantly slower than that of the control group
(p,0.01) (Figure 4B).
Discussion
In this study, we identified a novel nonphosphorylated motif
that bound to the SH2 domain of Grb7 protein with an affinity at
least comparable to the phosphorylated ligand pY (1180). This
twenty-two amino acid-motif contains conserved amino acids at
the N- and C-terminus and fifteen amino residues between that
are enriched with proline (21%), threosine (18%) and serosine
(13%) (Table 1). The binding affinity of the nonphosphorylated n–
Y–c peptide to the SAP SH2 domain is also similar to that of
phosphorylated ligands [33]. To our knowledge, this is the first
report to highlighting a protein domain that recognizes such an
extensive sequence motif structure (http://pawsonlab.mshri.on.
ca/index.php).
SH2 domains promote rapid and reversible signaling transduc-
tion [34]. If a nonphosphorylated peptide has a higher affinity to
the SH2 domain comparable to phosphorylated ligand, the
interaction becomes independent of phosphorylation and signaling
may not be rapidly attenuated [33]. The nonphosphorylated G7-
18 NATE peptide [27] has been used to inhibit Grb7 protein
functions. Mice injected with pancreatic cancer cells and treated
with the G7-18NATE peptide have fewer peritoneal metastases
compared to controls [3]. Inhibition of the G7-18NATE peptide
on the proliferation of several breast cancer cell lines, including
MDA-MB-231, ZR-75-30, SK-BR-3 and MDA-MB-361, is also
significant [29]. In our study, the proliferation of SK-BR-3 breast
cancer cells transfected with the 41-mRLUC-36Flag plasmid was
significantly slower than that of the mRLUC-36Flag control
group (Figure 4B).
We showed that the peptide 41 was more stable than peptide 10
(Figure 1A), possibly due to the presence of two tandem motifs in
peptide 41. Peptide 10 showed a slightly stronger BRET signals
compared to peptide 41 (Figure 2B). These nonphosphorylated
peptides may be optimized and useful for the rational design of
drugs targeted against cancers that harbor increased Grb7 protein
expression.
Materials and Methods
Materials
The ABL_1 and Grb2 plasmids were gifts from Professor Ruibao
Ren (Brandeis University, USA), and the Grb7 (BC006535) and
Grb14 cDNA (BC053559) plasmids were from the Proteintech
Group. The inserted sequences of the SH2 domains were as follows:
Grb7: N-IHRTQLWFHGRISREESQRLIGQQGLVDGLFLV-
RESQRNPQGFVLSLCHLQKVKHYLILPSEEEGRLYFSMDDG
QTRFTDLLQLVEFHQLNRGILPCLLRHCCTRVAL-C; Grb2:
N-EMKPHPWFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPG
DFSLSVKFGNDVQHFKVLRDGAGKYFLWVVKFNSLNELVD
YHRSTSVSRNQQIFLRDIEQVPQQP-C; ABL_1: N-SLEKHS-
WYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEG
Figure 1. The nonphosphorylated peptide 41 and the Grb7 SH2 domain are co-immunoprecipitated from transfected HEK293T
cells. A) Expression of nonphosphorylated peptides. B) Interactions between nonphosphorylated peptides and the Grb7 SH2 domain.
doi:10.1371/journal.pone.0029902.g001
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TTLHYPAPKRNK-C; and Grb14: N-QSSATNMAIHRSQPWF
HHKISRDEAQRLIIQQGLVDGVFLVRDSQSNPKTFVLSMS
HGQKIKHFQIIPVEDDGEMFHTLDDGHTRFTDLIQLVEFY
QLNKGVLPCKLKHYCARIAL-C.
In the mutation assay, the control and mutation sequences were
as follows:
10: N-AGVESLGIPNYTPTT PTLLLTRPLPGIPRGLRGW-
C;
10AM: N-AGVESL YTPTTPTLLLTRPLPGIPRGLRGW-C;
Figure 2. BRET assay of interactions between nonphosphorylated peptides and the Grb7 SH2 domain. A) Overlaid images of
transfected EYFP-fused proteins in living HEK293T cells at 480 nm. B) Quantification of the BRET luminescence ratios. The direct luminescence ratios
of 530/480 nm were on the top, and the relative luminescence ratios of 530/480 nm were on the bottom. The BRET reaction was initiated by the
coelenterazine (5.9 mM). The statistical analysis was based on eighteen group ratios, * represented statistical significance with p,0.05 and
** represented statistical significance with p,0.01.
doi:10.1371/journal.pone.0029902.g002
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Grb7 SH2 domain. A) Different concentrations of synthesized phosphorylated ligands pY (1180) (DEEYEpY(1180)MNRRR) from ErbB3 and the
nonphosphorylated ligands 41-A (VAVGIPTQPTTSSEPSPPSNPPWDPGRV) from the nonphosphorylated ligand 41 were added respectively into the
interacting complexes of Grb7 SH2 domain and peptide 41 (on the top). The bands were scanned and IC50 values were calculated (on the bottom). B)
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and 10CM: N-AGVESL YTPTTPTLLLTRPLP RGLRGW-
C.
In the co-immunoprecipitation assay, the mRLUC fragment
was generated by PCR amplification. The inserted sequence of the
Grb7 SH2 domain was as follows: N- IHRTQLWFHGRIS-
REESQRLIGQQGLVDGLFLVRESQRNPQGFVLSLCHLQKV
KHYLILPSEEEGRLYFSMDDGQTRFTDLLQLVEFHQLNRG
ILPCLLRHCCTRVAL-C. This sequence was inserted at the C
terminusoftheEGFPtag.The sequence ofpeptide 10wasasfollows:
N-GMWEGLEGGGVAGVESLGIPNYTPTTPTLLLTRPLPGIP
RGLRGWSLLRCCRLLCRNSYITAAPKHHHPLQTSPRGSPG
LQEFDIKLIDTVDLEGGPGTQFAL-C. The sequence of peptide
41 was as follows: N-VGTWTTRGPWCPCVAVGIPTQPTTS-
SEPSPPSNPPWDPGRVLLGRIVWPGLLALGIPTHHQNDTY
NSPHAHPNRDP-C. The sequence of peptide 10CM was as
follows: N-AGVESLYTPTTPTLLLTRPLPRGLRGW-C. The
nonphosphorylated peptide and the mRLUC fragment were
inserted at the N-terminus of the Flag tag. The mRLUC fragment
was fused with the nonphosphorylated peptide so that they could be
easily identifiable. The empty vector containing the mRLUC
fragment was used as the negative control.
The phosphorylated ligand pY (1180) (DEEYEpY(1180)MNRRR)
from the ErbB3 and the nonphosphorylated peptide 41-A (VAV-
GIPTQPTTSSEPSPPSNPPWDPG RV) from nonphosphorylated
peptide 41 were synthesized by the China Peptides Co., Ltd. The HPLC
purification analysis and MS quality analysis reports were obtained.
For the BRET assay, the EYFP fragment was generated by
PCR amplification. The ErbB3-mRLUC plasmid was constructed
by the Beijing Sino Biological Inc. The SH2 domain of Grb7 was
fused to the EYFP fragment, and the nonphosphorylated peptides
10 and 41 were fused to the mRLUC fragment. The Grb7 SH2
domain sequence was inserted at the C-terminus of the EYFP tag.
For the cell proliferation assay, the anti-Grb7 antibody (N-20,
Santa Cruz Biotechnology, USA) and the anti-Flag antibody
(M20008M, Abmart, China) were used for the western blot, and
MTS (Promega, USA) was used for the analysis of cell proliferation.
Figure 4. Effect of the nonphosphorylated peptide 41 on the proliferation of the SK-BR-3 breast cancer cells. A) Protein expression.
The endogenous Grb7 protein expression (left) and expression of the fusion protein of 41-mRLUC-36Flag (right) in the SK-BR-3 breast cancer cells
were identified by western blot. B) SK-BR-3 breast cancer cell proliferation analysis. Double-factor variance analysis was performed to analyze the
differences between the adjusted absorbance and different transfected cell groups, and between the adjusted absorbance and different time points.
Statistically significant differences existed in both of groups (n=10, p,0.001).
doi:10.1371/journal.pone.0029902.g004
Structural modeling for the nonphosphorylated peptide 41-A (VAV GIPTQPTTSSEPSPPSNPPWDPGRV) binding to the Grb7 SH2 domain was performed
with MOE. Left was the structural model of the Grb7 SH2/pY (1139) of ErbB2 [31], right was that of the Grb7 SH2/41-A. Red section represented a
helix; yellow represented b strand; white represented loop in the Grb7 SH2 domain; green represented the binding ligand; for the
nonphosphorylated peptide, left was the N-terminus, and right was the C-terminus.
doi:10.1371/journal.pone.0029902.g003
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Yeast two-hybrid system. The GAL4 BD-SH2 fusion bait
plasmids were transformed into the yeast strain CG1945 using the
lithium acetate protocol. The transformants were grown on SD/-
Trp plates and spread on SD/-Trp-His plates for self-activation
estimation. Those transformants without background growth or
growth inhibited by 3-amino-1, 2, 4-triazole were selected for the
subsequent screening. Approximately 3.01610
6 clones of the
random peptide library (Protocol No. PT303921, Clontech, USA),
as AD baits, were effectively transformed into yeast strain CG
1945 containing BD bait plasmids and used to be screened
according to the MATCHMAKER Two-Hybrid System protocol
(Cat. No. 630489, Clontech, USA). Plasmids of potential positive
transformants selected on plates with SD/-Trp-His-Leu medium
in the primary screening were isolated and retransformed into the
CG1945 cells containing the corresponding SH2 bait plasmids.
The improved LacZ assay was then performed. Clones that were
positive for all of the reporter assays and confirmed by three
independent improved LacZ tests were selected for specific
interactions [35].
Cell transient transfection. HEK293T cells [36] at 70%–
80% confluency were given fresh DMEM (high glucose) culture
medium and transfected with plasmids using the calcium
phosphate method. Samples were collected at 36 h after
transfection.
Co-immunoprecipitation assay and western blot analy-
sis. HEK293T cells were washed 5 times with ice-cold PBS
buffer and scraped off the plates into cell lysis buffer (1% Nonidet
P-40, 0.02 M TRIS (pH 7.5), 0.15 M sodium chloride, 0.001 M
EDTA, 0.5% sodium deoxycholate, 0.1% SDS and 0.001 M
PMSF). Lysates were incubated on ice for 5 minutes, vortexed 2
times for 30 seconds each and centrifuged at 12,000 rpm for
15 minutes at 4uC. After centrifuging twice, the supernatant was
incubated with anti-Flag antibody (1:100, M20008M, Abmart,
China) for 6–8 h at 4uC. Protein G agarose (40 mL) was added into
1 mL of the above mixture and coupled to the anti-Flag antibody
for 3 h at 4uC. The immunoprecipitates were washed 2–3 times
with PBS buffer (PH 7.4), and the sediments were diluted with
56SDS electrophoresis buffer and heated at 97uC for 10 minutes.
The proteins were separated by SDS-PAGE and transferred to
PVDF membranes (IPVH00010, Millipore, USA). The
membranes were incubated with anti-GFP antibody (1:2000,
P30010, Abmart, China) and goat anti-rabbit secondary antibody
(1:4000, M21002, Abmart, China) to identify target proteins. For
the competition analyses, the immunoprecipitation complexes
were mixed with anti-Flag antibody and different concentrations
of the synthesized phosphorylated ligands or the
nonphosphorylated ligands. The proteins were separated by
SDS-PAGE, and the SH2 domain of Grb7 protein was analyzed
using anti-GFP antibody. Western blot analysis was carried out
using the Image J [37], the IC50 values were calculated by
regression analyses using SPSS 17.0.
Bioluminescence Resonance Energy Transfer
(BRET). In BRET, the Renilla luciferase (mRLUC) is fused to
the candidate protein, and the green fluorescent protein mutant
(EYFP) is fused to the target protein. Interactions between the two
fused proteins bring the luciferase and the green fluorescent
protein into close proximity, which promotes resonance energy
transfer from mRLUC to EYFP [38]. Then EYFP is excited at
530 nm, and the emission is used to determine the binding
between the two interacting proteins. In this study, HEK293T
cells were collected at 36 h after transfection, 100 mL of mixed cell
suspension was added to the u-bottom 96-well microtiter plates
(Corning, USA) before measurement. The measurement of
bioluminescence, with rasters of 460/40 nm and 518/20 nm,
was performed on Synergy4 Multi-Mode Microplates Readers
(BioTek, USA). The BRET reaction was initiated by 5.9 mM
coelenterazine (Promega, USA). Data were analyzed by one-factor
analysis of variance using SPSS 17.0.
Structural model of Grb7 SH2 domain binding to nonpho-
sphorylated peptide. The structure of the nonphosphorylated
ligand 41-A (GIPTQPTTSSEPSPPSNPP WDP) was first built by
MOE. This sequence had no homology sequence with known
structure in the Protein Date Bank (PDB) database and no
predicted secondary structure, such as a helix or b strand element.
Therefore, a linear, extended conformation was set as the primary
conformation of this ligand. Then, the energy of this ligand was
minimized in an AMBER99 force field to build its final
conformation for docking. Then the structure of the human
Grb7 SH2 domain complex with a ten amino acid-peptide was
downloaded from the PDB database (ID: 2l4k). The structure of
the SH2 domain was extracted for docking. Thus, a docking
method was used to predict the structure of the domain-ligand
complex.
Cell proliferation assay. The MTS cell proliferation assay
was performed to analyze the proliferation of SK-BR-3 breast
cancer cells (Cell culture center of PUMC, China) according to the
manufacturer’s instructions (Promega, USA). SK-BR-3 cells at
70%–80% confluency were transiently transfected respectively
with plasmids of 41-mRLUC-36Flag or mRLUC-36Flag and
Mega Tran 1.0 (OriGene, USA). Beginning from 12 h after
transfection, 400 mg/mL G418 (11811-023, Invitrogen, USA) was
used to select for the transfected cells [39]. The u-bottom 96-well
microtiter plates (Corning, USA) were seeded with approximately
7.50610
3 cells per well at 18 h after transfection. 20 mL of MTS
was added into 100 mL of cell culture medium, and the mixtures
were incubated at 37uC for 1 h before measurement. The
absorbance at 492 nm of transfected cells and control DMEM
medium was measured separately at 18 h, 24 h, 36 h, 48 h and
60 h after transfection on Synergy4 Multi-Mode Microplates
Readers (BioTek, USA). The absorbance was adjusted by
differences in the absorbance between cell culture medium and
control medium without seeded cells. The data were analyzed by
double-factor variance analysis using SPSS 17.0.
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